目的 探讨持续皮下胰岛素输注(CSII)治疗2型糖尿病(T2DM)的疗效及安全性.方法 将我院收治的176例T2DM患者随机分为CSII组(88例)和胰岛素多次皮下注射(MSII)组(88例).观察两组治疗前后血糖水平、血糖达标时间、胰岛素总用量及低血糖发生率.结果 治疗后两组血糖均较治疗前显著下降(P＜0.05)；两组间血糖浓度比较,差异无统计学意义(P＞0.05)；两组血糖达标时间、胰岛素总用量比较差异有统计学意义(P＜0.05) ;CSII组低血糖发生率为5.7％,显著低于MSII组的15.9％,差异有统计学意义(P＜0.05).结论 应用CSII治疗新诊断的T2DM患者,可更有效地控制血糖,减少低血糖的发生,是一种安全可靠的糖尿病强化治疗方法.%Objective To explore the efficacy and security of continuous subcutaneous insulin infusion (CSII) in the treatment of type 2 diabetes mellitus (T2DM). Methods 176 patients with T2DM were randomly divided into two groupst:88 cases in CSII group and 88 cases in multiple subcutaneous insulin infusion (MSII) group. Blood glucose level, the time to reach normal blood glucose level,the total dosage of insulin and the incidence of hypoglycemic were measured before and after treatment. Results After 14 days of treatment, the blood glucose level in both groups was significantly decreased (P<0. 05), but there was no statistical difference between the two groups (P>0. 05). There were significantly difference on the time to reach normal blood glucose level and the total dosage of insulin between the two groups (P< 0.05). The incidence of hypoglycemic between the two groups (5.7% vs. 15.9%) was significantly different (P< 0. 05). Conclusion CSII is more effective and safer in controlling blood glucose level more effectively and hypoglycemic for the newly diagnosed T2DM patients.
展开▼
